Cheat sheet

CDR CSO Cheat Sheet

Practice this exam

Cancer and Cancer Treatment

  • 20.8% of exam
  • Treatment modalities Symptom recognition Urgent escalation Functional status

Nutrition Assessment

  • 33.6% of exam
  • Intake and body composition PG-SGA and GLIM Requirements and social context Laboratory interpretation

Nutrition Interventions

  • 28.0% of exam
  • Individualised routes Refeeding precautions Monitoring and referral Care coordination

Education and Counseling

  • 17.6% of exam
  • Teach-back Food and supplement safety Survivorship and goals Community education

Quick Facts

  • Questions 150: 125 scored + 25 pretest
  • Testing 180 minutes; 20-minute tutorial extra
  • Fee USD 350 examination fee
  • RD Status At least 2 years
  • Initial Practice 2,000 hours within preceding 5 years
  • Substitutions Approved: up to 40% / 800 hours
  • Retake 60 days; CDR reauthorization
  • Validity 5 years; eligible pilot alternative

Irinotecan Diarrhoea Timing CA

Early

  • During/shortly after infusion
  • Cholinergic symptoms may occur

Late

  • Usually more than 24 hours
  • Dehydration or sepsis risk
  • Use the oncology treatment plan

Treatment and Functional Status CA

  • TNM Primary tumour, nodes, distant metastasis
  • Histological Grade Differentiation; distinct from anatomical stage
  • ECOG 3 Limited self-care; bed/chair >50% waking
  • ECOG 4 Complete disability; no self-care
  • Early Irinotecan Diarrhoea During/shortly after infusion; cholinergic symptoms
  • Late Irinotecan Diarrhoea Usually >24 hours; dehydration risk

Treatment Effects and Escalation CA

  • Neutropenia With Abdominal Pain Urgent assessment; no automatic PN
  • Checkpoint-Inhibitor Colitis Escalate diarrhoea, bleeding and dehydration
  • CAR-T Altered Alertness Urgent assessment; check swallowing safety
  • Head-and-Neck Radiotherapy Monitor intake, mouth and swallowing
  • Pelvic Radiotherapy Diarrhoea Assess causes, losses and tolerance
  • Allogeneic HSCT Assess GVHD, toxicity and intake

GLIM: One AND One NU

  • Phenotype AND etiology; assess before diagnosing
  • Weight, BMI or muscle Intake/assimilation or inflammation Severity uses phenotypic criteria

Screening vs Assessment NU

Screening

  • Rapid risk identification
  • Triggers further evaluation

Assessment

  • Characterises nutritional problems
  • Supports diagnosis and care plan
  • Risk is not a complete diagnosis

Assessment and Triage Pathway NU

  • Screen indicates nutritional risk → Complete assessment and symptom review ( Include access and cultural context )
  • PG-SGA score is ≥9 → Arrange urgent symptom/nutrition intervention ( Global category requires separate assessment )
  • GLIM diagnosis is considered → Find phenotypic and etiologic evidence ( Assess all criteria )
  • Weight rises despite poor intake → Examine fluid and body composition ( Weight gain can mask tissue loss )

Screening, Assessment and Cachexia NU

  • Positive Screening Risk identified; comprehensive assessment follows
  • PG-SGA Numerical Score ≥9 Urgent symptom and nutrition intervention
  • PG-SGA Global A/B/C Separate assessment; not score bands
  • GLIM Diagnosis ≥1 phenotypic AND ≥1 etiologic criterion
  • Fearon: Six-Month Weight Loss >5%; assess full clinical syndrome
  • Fearon Alternative >2% loss plus BMI<20 or sarcopenia

PG-SGA Score vs Global Category NU

Numerical score

  • Intervention triage
  • ≥9 signals urgent need

A/B/C category

  • Clinical nutritional-status judgement
  • Not numeric score bands
  • Record score and global category separately

Weight, Muscle and Fluid NU

  • Weight-Loss Percentage Lost weight ÷ usual weight ×100
  • 80 kg → 74 kg 7.5% loss; interpret timeframe
  • High BMI Does not exclude muscle depletion
  • Muscle Thresholds Method and population must match
  • Ascites/Oedema Assess fluid; no fixed-kilogram subtraction
  • Albumin Inflammation-sensitive; not stand-alone nutrition diagnosis

Food Deprivation vs Cachexia NU

Food deprivation

  • Insufficient nutrient supply
  • Investigate access and reversible barriers

Cancer cachexia

  • Intake plus metabolic disturbance
  • Nutrition alone may not reverse
  • Treat causes as well as intake

Biochemistry and Clinical Context NU

  • Refeeding Electrolytes Track phosphorus, potassium and magnesium
  • Refeeding Diagnosis Post-feeding change plus clinical context
  • Tumour Lysis Pattern High potassium/phosphate/urate; low calcium
  • Tumour Lysis Response Urgent team care; individualise electrolytes
  • Ferritin Inflammation may mask iron deficiency
  • Food Insecurity Assess access, affordability and facilities

Requirements and Assessment NU

  • ESPEN Estimated Energy 25–30 kcal/kg/day; individualise
  • ESPEN Protein (g/kg/day) Above 1; if possible, 1.5
  • Reference Weight Assess fluid and body composition
  • Gastrectomy Monitor intake, B12 and iron
  • Abiraterone Food Rules Check exact formulation and label
  • GLIM 2026 Intake Guidance Usual intake; symptoms and duration

Refeeding: Before, Begin, Reassess NU

  • Thiamine, electrolytes, cautious calories, monitoring
  • Severely low: delay and correct Count IV dextrose Advance with clinical stability

Enteral vs Parenteral Nutrition NU

EN

  • Uses gastrointestinal tract
  • Preferred when feasible

PN

  • Intravenous nutrient delivery
  • When EN is insufficient/impossible
  • Individualise by function, goals and tolerance

Route Selection After Assessment NU

  • Oral intake is safe and feasible → Optimise foods, symptoms and supplements ( Monitor achieved intake )
  • Oral measures remain inadequate → Use enteral support when feasible ( Assess swallowing and bowel function )
  • Enteral support insufficient or impossible → Consider supplemental or total PN ( Balance expected benefit and burden )
  • Clinical state or goals change → Reassess route and nutrition targets ( Avoid automatic treatment duration )

Gastrointestinal Nutrition Decisions NU

  • Faecal Elastase <100 μg/g Supports EPI; formed stool sample
  • Faecal Elastase 100–200 μg/g Indeterminate; assess further
  • Adult PERT Starting Dose ≥40,000 USP lipase units/meal
  • PERT Snacks Half meal dose; take with food
  • Chyle Leak Individualise fat; preserve essential fats
  • High Ileostomy Output Assess hydration; specialist fluid plan

At-Risk Adult Refeeding Pathway NU

  • Before feeding or IV dextrose → Give thiamine; check P/K/Mg ( ASPEN: thiamine 100 mg )
  • Electrolytes are severely low → Delay initiation/increases; replace and monitor ( Individualise for renal and clinical status )
  • Starting feeds with monitoring established → 10–20 kcal/kg across first day ( Count dextrose from all sources )
  • Electrolytes fall precipitously → Reduce calories; treat and reassess ( Advance only with clinical stability )

Nutrition Routes and Refeeding NU

  • Oral Intake Inadequate Counsel, fortify, consider supplements
  • Oral Measures Insufficient Enteral nutrition when feasible
  • Enteral Support Inadequate/Impossible Consider PN; assess benefit and burden
  • ASPEN At-Risk Adult Thiamine 100 mg before feeding/dextrose
  • ASPEN Calories: First 24 Hours 10–20 kcal/kg; include IV dextrose
  • Severely Low Electrolytes Delay feeding/increases; treat and monitor

Monitoring and Team Decisions NU

  • PN Monitoring Glucose, electrolytes, fluid, triglycerides, liver
  • Gastrostomy Before Radiotherapy Individual risk-benefit discussion; not universal
  • Symptomatic GI GVHD Choose route by function and tolerance
  • Swallowing Red Flags Cough, wet voice, suspected aspiration
  • Monitoring Plan Define outcomes, timing and response
  • Home Enteral Coverage CMS: long and indefinite impairment

Food Safety: Four Actions ED

  • Clean, Separate, Cook, Chill
  • Choose safer foods Check preparation temperatures Follow transplant precautions

Laboratory Signal vs Clinical Evidence ED

Laboratory/animal

  • Mechanistic signal
  • May prompt precaution

Human clinical

  • Patient outcomes studied
  • Design and context still matter
  • Laboratory results do not prove harm

Counselling and Shared Decisions ED

  • Patient proposes restrictive cancer diet → Explore aims and explain evidence ( Assess risk without dismissing concerns )
  • Patient uses supplements or herbs → Record product; request interaction review ( Distinguish preclinical from human evidence )
  • Teaching an individual or group → Agree practical goals; use teach-back ( Adapt language, access and preferences )
  • Prognosis or goals change → Discuss expected benefit and burden ( Comfort care includes mouth care )

Education, Safety and Goals ED

  • Food-Safety Framework Clean, separate, cook and chill
  • Immunosuppression: Deli Meats Heat to 165°F or steaming
  • EGCG–Bortezomib Evidence Laboratory/animal findings; human significance uncertain
  • High-Dose Antioxidants No routine recommendation during treatment
  • WCRF Cooked Red Meat Limit about 350–500 g/week
  • Dying Phase Prioritise comfort and individual goals

Common Traps

PG-SGA Triage versus Global Category

  • Score ≥9: urgent nutrition/symptom intervention ≠ Global C: separate clinical assessment

Nutrition Route: Bowel Function Matters

  • Severe GI symptoms: assess function/tolerance ≠ Automatic PN solely from symptom severity

Fluid-Affected Weight versus Fixed Subtraction

  • Fluid shifts can conceal tissue loss ≠ Universal kilogram subtraction for dry-weight

Refeeding: Serial Change versus Snapshot

  • After increased calories: serial electrolyte changes ≠ Diagnosis from one phosphorus cutoff

EGCG–Bortezomib: Evidence Level Matters

  • EGCG–bortezomib preclinical findings ≠ Proof of human clinical antagonism

CSO Recertification: Standard versus Limited Alternative

  • Standard route: examination ≠ Eligible longitudinal-assessment pilot: alternative route

Last Minute

  • 1. Separate 150 total from 125 scored
  • 2. Calculate weights using scored items
  • 3. PG-SGA score differs from global category
  • 4. GLIM requires phenotype AND etiology
  • 5. Interpret weight alongside fluid and muscle
  • 6. Escalate urgent oncology symptoms
  • 7. Individualise energy, protein and reference weight
  • 8. Choose route by function and goals
  • 9. Use refeeding precautions when indicated
  • 10. Review exact drug formulation and supplements
  • 11. Adapt counselling to access and culture
  • 12. Document outcomes and reassessment

CDR CSO Board Certified Specialist in Oncology Nutrition

  • Practice Questions 147 questions Study Guide 43 topics Cheat Sheet 60 facts Flashcards 50 cards Games 20 terms Free CE Podcast
  • Word games 20 terms Guess the Term T E R M S Read the clue and guess the term in 6 tries. Word games 20 terms Term Match Swap tiles to line up three of the same term. Word games 20 terms Term Pairs ? ✓ ✓ ? ? Flip two cards at a time to find matching terms. Word games 20 terms Term Search Q T E R M X Find five hidden terms in a grid of letters.